Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.72 |
| ▸ | CES2 | O00748 | 2/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8534398 | 0.84 | GSK3B (0.66) | GSK3BCES2CES1PTPN1SRD5A2 | |
| SCHEMBL6784646 | 0.84 | GSK3B (1.00) | GSK3BCES2CES1PTPN1SRD5A2 | |
| SCHEMBL2075210 | 0.82 | GSK3B (0.63) | GSK3BCES2CES1PTPN1SRD5A2 | |
| SCHEMBL11461859 | 0.82 | HDAC1 (0.52) | GSK3BSRD5A2TRPV1MEN1TSHR | |
| SCHEMBL8553654 | 0.82 | CES2 (0.65) | GSK3BCES2CES1PTPN1SRD5A2 | |
| SCHEMBL627504 | 0.81 | CES2 (0.55) | GSK3BCES2TSHR | |
| SCHEMBL19866845 | 0.81 | GSK3B (0.61) | GSK3BCES2CES1PTPN1SRD5A2 | |
| SCHEMBL21565745 | 0.81 | GSK3B (0.61) | GSK3BCES2CES1PTPN1SRD5A2 | |
| SCHEMBL19520441 | 0.81 | GSK3B (0.61) | GSK3BCES2CES1PTPN1SRD5A2 | |
| SCHEMBL5951864 | 0.81 | GSK3B (0.61) | GSK3BCES2CES1PTPN1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8648200-B2 | Imidazole derivatives useful for the treatment of arthritis | ELI LILLY AND COMPANY (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120302608-A1 | Novel Imidazole Derivatives Useful for the Treatment of Arthritis | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012161965-A1 | NOVEL IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF ARTHRITIS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7449483-B2 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7314884-B2 | non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile | HOFFMANN-LA ROCHE INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | disclosed |
| US-6172102-B1 | POLLAKIURIA OR URINARY INCONTINENCE | NIPPON SHINYAKU CO., LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| US-5998459-A | INCOTINENCE THERAPY | NIPPON SHINYAKU CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0617031-B1 | Orally active azole derivates | URIACH & CIA SA J (ES) | 1998-09-16 | — | — | EP | disclosed |
| US-5760245-A | FUNGICIDES | J. URIACH & CIA S.A. (ES) | 1998-06-02 | — | — | US | disclosed |
| EP-0842923-A1 | PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-05-20 | — | — | EP | disclosed |
| US-5646294-A | FUNGICIDES | J. URIACH & CIA. S.A. (ES) | 1997-07-08 | — | — | US | disclosed |
| US-5478826-A | Fungicides for human, animal and plants | J. URIACH & CIA. S.A. (ES) | 1995-12-26 | — | — | US | disclosed |
| EP-0617031-A1 | Orally active azole derivates | J. URIACH & CIA. S.A. (ES) | 1994-09-28 | — | — | EP | disclosed |
| EP-0612734-A1 | Novel orally active antifungal agents | J. URIACH & CIA. S.A. (ES) | 1994-08-31 | — | — | EP | disclosed |
| US-4690931-A | IN TREATMENT OF ANOXIA OR BRAIN DAMAGE | SYNTHELABO (FR) | 1987-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302608-A1 | Novel Imidazole Derivatives Useful for the Treatment of Arthritis | F12, IL1RN, ARG1 | GSK3B 3749/4885CES2 4735/4885CES1 3526/4885 |
| US-20070259925-A1 | DPP IV INHIBITORS | DPP4, DPP3, DPP7 | GSK3B 500/4885CES2 442/4885CES1 108/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | GSK3B 546/4885CES2 3644/4885CES1 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.